Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;239(2):405-11.
doi: 10.1016/j.atherosclerosis.2015.01.022. Epub 2015 Jan 28.

Soluble P-selectin predicts lower extremity peripheral artery disease incidence and change in the ankle brachial index: the Multi-Ethnic Study of Atherosclerosis (MESA)

Affiliations

Soluble P-selectin predicts lower extremity peripheral artery disease incidence and change in the ankle brachial index: the Multi-Ethnic Study of Atherosclerosis (MESA)

Christina L Wassel et al. Atherosclerosis. 2015 Apr.

Abstract

Objective: To determine the association of circulating P-selectin with prevalent and incident peripheral artery disease (PAD), the ankle brachial index (ABI), and change in the ABI.

Methods: The Multi-Ethnic Study of Atherosclerosis (MESA) is a prospective population-based cohort study including 6814 European descent, African American, Hispanic and Chinese men and women aged 45-84 at baseline. Four clinical exams took place after the baseline exam. After excluding those with ABI>1.4, prevalent and incident PAD were defined as an ABI≤0.90. ABI progression was defined as progression from a normal ABI (0.91-1.4) to abnormal (≤0.90 or >1.4) at a later exam.

Results: In adjusted models, each SD (13 ng/mL) higher P-selectin was significantly associated with 0.007 lower ABI (95% CI ((-0.011, -0.004)), p < 0.001), and an average change in the ABI of -0.006 ((-0.010, -0.003, p < 0.001). P-selectin was significantly associated with a 1.17-fold greater odds of prevalent PAD ((1.02, 1.33), p = 0.03), and a 30% greater risk of incident PAD ((1.11, 1.53), p = 0.001), as well as progression from a normal ABI to an ABI≤ 0.90 (p = 0.003), but not to an ABI>1.4 (p = 0.96). Addition of P-selectin to models containing traditional PAD risk factors and markers of inflammation/coagulation significantly improved the net reclassification for ABI progression (p = 0.03), but was only marginally significant for incident PAD (p = 0.06).

Conclusions: P-selectin is significantly associated with the development of PAD. However, further research is needed in population-based studies to confirm prospective associations of P-selectin with incident PAD and change in the ABI, as well as its potential predictive ability.

Keywords: Ankle brachial index; Incidence; Net reclassification improvement; P-selectin; Peripheral artery disease; Prediction.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have none to disclose.

Figures

Figure 1
Figure 1. Mean Soluble P-selectin levels by ABI Category at Exam 3 and ABI progression from Exam 3 to Exam 5
Figure 1 shows least squares means of soluble P-selectin, adjusted for age, race/ethnicity and sex, by ABI category at Exam 3, and progression of ABI from normal at Exam 3 (0.91–1.4) to abnormal (≤0.90 or >1.4) at Exam 5. P-selectin in ng/mL is shown on the Y-axis, with ABI categories on the X-axis. ABI≤0.90 is represented by red bars, ABI>1.4 by green bars, and 0.90
Figure 2
Figure 2. Association of soluble P-selectin with progression of the ABI from Exam 3 to Exam 5
Figure 2 is a forest plot that displays the association of P-selectin per standard deviation for ABI progression from Exam 3 to Exam 5. Values shown are odds ratios with 95% CIs for varying levels of model adjustment as described in the text. Only participants with a normal ABI (0.91–1.4) at Exam 3 were included, and were evaluated for progression to an abnormal ABI at Exam 5 (ABI≤0.90 or ABI>1.4), with the reference group as participants who remained in the normal ABI category from Exam 3 to Exam 5 (ABI of 0.91–1.4). Model adjustments include demographics (age, race/ethnicity, and gender), with additional adjustment for body mass index, ever smoking, hypertension, diabetes, estimated glomerular filtration rate, fasting glucose, LDL cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, diastolic blood pressure; a final model additionally adjusts for CRP, IL-6, fibrinogen, and D-dimer.

Similar articles

Cited by

References

    1. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013 - PubMed
    1. Ankle Brachial Index Collaboration. Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197–208. - PMC - PubMed
    1. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–386. - PubMed
    1. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006;114:688–699. - PubMed
    1. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004;109:733–739. - PubMed

Publication types